Francis Collins positive about consumer genetics

Francis Collins, former Director of the National Human Genome Research Institute, in a presentation last week (as reported by GenomeWeb Daily News):

He also said that he is "delighted" that direct-to-consumer genetic
testing services are being offered, even though the field "has become a
favorite whipping boy for some of us." He said it is good "that the
public is having the chance to learn about their genomes if they think
they want to know ... and that companies are doing this in a responsible
way. But, of course, there are some things on the web that are not
responsible."

In addition, Collins endorsed the call by the Secretary's Advisory
Committee on Genomics, Health and Society to create a public database
of information that would give consumers "a place to go to seek
objective information about the clinical validity and clinical utility
of these tests.

"It's disturbing to see that there hasn't been much progress on that
because it makes so much sense," he said, adding that without "some
objective way to evaluate" these gene tests there will be "some other
entities on the scene that are a little less responsible."

Given the major role that Collins is likely to play in
determining the agenda of the Obama government for personalised
medicine, consumer genetics companies must have been pleased to hear
his generally up-beat views on their industry.

As for the database of information for consumers - we've seen this possibility mooted several times by different groups (both public and private), but little visible progress. Providing an objective guide to consumers seeking to navigate the complexities of DTC genetic testing would provide far more useful customer protection than excessively strict regulation. I hope we see genuine movement on this front in the very near future.

Subscribe to Genetic Future.

Categories

More like this

What a fabulous combination. This week, Congress has held hearings on the direct-to-customer ('DTC') genetic testing industry. It appears, based on previous statements by FDA officials, that they have publicly contradicted themselves--or been willfully ignorant--about the larger scientific…
So, in some quarters, there's been wailing and gnashing of teeth over the Congressional hearings about the direct-to-customer ('DTC') genetic testing industry. I've discussed why I don't think regulation is a disaster before, but I'll add one more issue to the mix: maintaining subject…
As part of his Gene Week celebration over at Forbes, Matthew Herper has a provocative post titled "Why you can't have your $1000 genome". In this post I'll explain why, while Herper's pessimism is absolutely justified for genomes produced in a medical setting, I'm confident that I'll be obtaining…
Welcome to the new look Genetic Future, now hosted on ScienceBlogs. In around five years, a complete genome sequence will be readily affordable for most citizens of wealthy industrialised nations - even those of us on a researcher's salary. At the same time we will have access to vast amounts of…